Avidity

#JPM21: Avidity CSO Art Levin runs full speed to the clinic with 'dream' antibody oligonucleotide conjugate therapy
Endpoints
Thu, 01/14/21 - 10:34 am
Avidity
JPMHC 2021
oligonucleotide-based therapies
muscle diseases
Eli Lilly-backed biotech grabs $100M to dispatch antibody-oligonucleotide conjugates after muscular dystrophy
Endpoints
Wed, 11/13/19 - 10:09 am
myotonic muscular dystrophy
Eli Lilly
R&D
Avidity
Lilly pays $35M up front to partner with Avidity on oligo conjugates
BioCentury
Mon, 04/22/19 - 10:24 am
Eli Lilly
Avidity
oligo conjugates